Fulvestrant?Faslodex? 0.25?g | EVER Pharma (Germany) | Price comparison Subtotal: $2.00
Bortezomib 1?mg Wholesale price comparison
$1.00
Bortezomib Injection is a proteasome inhibitor used in preclinical oncology research, particularly for multiple myeloma, mantle cell lymphoma, and various solid tumor models. Each vial contains 1?mg of bortezomib (boronic acid dipeptide), manufactured by Zhengda Tianqing Pharmaceutical Group Co., Ltd., approved under China NMPA H20183261 (product code: 86901523002086).
?? For laboratory research use only.?Please consult the staff for other purposes?
描述
Bortezomib Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Bortezomib Injection |
| Generic Name | Bortezomib (boronic acid dipeptide proteasome inhibitor) |
| CAS Number | 179324?69?7 (free drug base) |
| Molecular Formula | C??H??BN?O? |
| Molecular Weight | ~384.24?g/mol |
| Dosage Form | Sterile injectable solution (lyophilized powder for reconstitution) |
| Strength | 1?mg per vial |
| Pack Size | 1 vial per box |
| Approval Number | H20183261 (China NMPA) |
| Product Code | 86901523002086 |
| Manufacturer | Zhengda Tianqing Pharmaceutical Group Co., Ltd. |
| Storage | Store below 30?°C, protect from light |
| Intended Use | Laboratory research use only |
Mechanism of Action
Bortezomib selectively and reversibly inhibits the 26S proteasome, targeting the ?5 catalytic subunit (PSMB5). This causes accumulation of misfolded and regulatory proteins (e.g., p21, p27, p53, I?B?), leading to cell-cycle arrest, apoptosis, reduced angiogenesis, and suppressed tumor growth.
en.wikipedia.org+2pmc.ncbi.nlm.nih.gov+2biomarkerres.biomedcentral.com+2biomarkerres.biomedcentral.com+2en.wikipedia.org+2de.wikipedia.org+2
Research Applications & Pharmacology
-
Oncology models: Demonstrates antitumor efficacy in preclinical studies of multiple myeloma, mantle-cell lymphoma, lung, breast, prostate, pancreatic, colon cancers, melanoma, and head & neck cancers, resulting in reduced tumor growth, angiogenesis, metastasis, and extended survival.
-
Mechanism-focused studies: Shows effects on NF??B inhibition, JNK activation, ER stress pathways, and apoptotic signaling.
-
Combination research: Enhances efficacy when used with chemotherapy, radiation, immunotherapy, and novel agents without increasing toxicity in animal models.
-
Pharmacokinetics: Administered IV or SC. Half-life ~9–15 hours; proteasome inhibition sustains ~72 hours post-dose.
Safety Profile & Key Precautions
Preclinical and clinical observations include:
-
Myelosuppression: Neutropenia, thrombocytopenia
-
Gastrointestinal: Nausea, diarrhea
-
Neuropathy: Sensory peripheral neuropathy
-
Other effects: Fatigue, fever, rash, hypotension, tumor lysis syndrome
-
Lethality in high-dose animal studies (?1.5?mg/kg) with weight loss and GI inflammation
Lab Handling Suggestions:
-
Reconstitute under sterile conditions
-
Dose carefully in vivo, monitor blood count and weight
-
Ensure PPE and safe disposal protocols are followed
?? Research?Use Disclaimer
This product is intended exclusively for laboratory research and is not approved for clinical, therapeutic, diagnostic, or veterinary use. Improper use may lead to safety hazards and invalidate experimental results.
其他信息
| 重量 | 1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Fulvestrant?Faslodex? 0.25?g | EVER Pharma (Germany) | Price comparison
Fluvestrant (250?mg/5?ml) injectable solution, 2-vial set by EVER?Pharma Jena GmbH, Germany. A potent selective estrogen receptor degrader (SERD) used in advanced breast cancer research.
?? For laboratory research only – Not for human consumption or therapeutic use. $2.00 -
Granisetron Hydrochloride Dispersible Tablets Price comparison
A 5-HT? receptor antagonist—Granisetron Hydrochloride Dispersible Tablets by Guangxi Mingjian Pharmaceutical Co., Ltd. (Guimingjian). Packaged as 1?mg tablets, 4 tablets per blister × 2 blisters per box. Approved in China (NMPA No. H20020303; product code 86905130000183). Primarily intended for clinical prevention and treatment of nausea/vomiting induced by chemotherapy, radiation, or surgery. For research use only $1.00 -
Reduced Glutathione Injection 0.6?g × 10 Vials – Ruiyang | Price comparison
Ruiyang Reduced Glutathione Injection (0.6?g per vial × 10) by Ruiyang Pharmaceutical Co., Ltd. Ideal for antioxidant, detoxification, and hepatic-protection research in metabolic and oxidative stress studies.
?? For laboratory research use only – Not for human consumption or therapeutic use. $2.00 -
Rilertinib Mesylate Tablets (Sanrisso®) – 100?mg × 20 Tablets per Bottle
Rilertinib mesylate (Sanrisso®), developed by Nanjing Sanhome Pharmaceutical Co., Ltd., is a third-generation EGFR-TKI approved by China's NMPA (Approval No. H20240020; Drug Code: 86901583000930). Each bottle contains 20 tablets of 100?mg each. Strictly for laboratory research use only—not for clinical or human use. $1.00
评价
目前还没有评价